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ABSTRACT 
EFFICACY OF ZINC SUPPLEMENTATION 
IN REDUCING THE INCIDENCE OF RECURRENT VAGINITIS
By
Bonnie R. Bartz
The purpose of this study was to evaluate the efficacy of zinc supplementation in 
reducing the incidence of recurrent bacterial vaginosis (BY) and vulvovaginal candidiasis 
(W C). Forty-one subjects were selected from researcher’s patients based on at least two 
episodes of vaginitis in a six-month period. A control group (placebo) and an experimental 
group (30 mg zinc gluconate) were randomly formed from this selection.
Evaluation of vaginitis status was accomplished through wet mounts, pH test, and 
KOH whiff tests at the initial, 3, and 6-month intervals. Subjects sought treatment for 
vaginitis when symptomatic.
A t-test analysis showed no statistically significant difference in the overall incidence 
of vaginitis between the control group and the experimental group (t = 1.45, df = 22, p =
0.16). The incidence of W C  in the zinc group decreased from 19 to 5 post treatment (t = 
2.23, p = 0.021).
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CHAPTER I 
INTRODUCTION
Vaginitis accounts for more visits to the obstetrics and gynecology office than any 
other female condition (Mead & Eschenbach, 1998). An estimated 5-10 million office 
visits per year are made due to vaginitis (Faro, 1994). In 1991, U.S. women spent over 
$ ICO million dollars on over the counter yeast treatments (Foxman, 1997).
Bacterial vaginosis (BY) is the most common vaginal infection. It is estimated that 
50 - 64% of sexually active women have at least one episode of BY (Selleck, 1997). 
Vulvovaginal candidiasis (yeast infections or VYC) are the second most common vaginal 
infection. An estimated 75% of women will have a VYC infection at least once in their lives 
(Nyiijesy, 1997). Approximately 5% of women with one episode of YYC will suffer 
difficult or recurrent infection. Recurrent infection is commonly defined as four 
mycologically proven symptomatic episodes of YYC in 12 months (Nyiijesy, 1997).
Recent research links BY to serious gynecological, obstetrical, and general medical 
risks, including upper reproductive tract and postoperative infections, adverse pregnancy 
outcomes, preterm labor, cervical dysplasia, mucosal barrier disruption, and increased 
transmission of Human Immunodeficiency Virus (HTY), Human Papilloma Virus (HPY), 
and Herpes Simplex Virus (HSY) (Secor, 1997). Little research has been done in finding 
nursing interventions that may help decrease the recurrence rate of vaginitis in women who 
are prone to recurrent infections.
Health care professionals have long known that zinc is needed by the human body 
for optimal well-being, especially for maintaining a healthy immune system. The use of 
topical zinc has been recommended in the treatment of genital herpes (Northrup, 1994).
High levels of serum zinc have been observed as a protective factor against HPV in women 
(Liu, Soong, Alvarez, & Butterworth, 1995) and HTV (Secor, 1997). Zinc has also been 
found to have an antitrichomonal activity (Houang, Ahmet, & Lawrence, 1996). Zinc 
deficiency has been demonstrated to reduce the immunity of inbred strains of mice to 
infection with C. albicans (yeast), while zinc excess or sufficiency was a protective factor 
against Candida (Edman, Sobel, & Taylor, 1986).
This author identified no studies on the use of supplemental zinc to help prevent 
vaginal infections. “Research that describes the microfloral ecosystem of the vagina or 
examines therapeutic or preventive modalities based upon écologie tenets is sparse” 
(Overman, 1993, p. 146). “The scientific literature increasingly supports the impact of 
lifestyle on health maintenance and disease prevention; yet, there are few scientific data to 
support the role of nutrition, exercise, stress reduction, and general health maintenance in the 
management of sexually transmitted diseases (STDs) and vaginitis” (Roe & Gudi, 1997, p. 
275).
Many patients seek a natural remedy for health care ailments. “In a given year 
about a third of all American adults use unconventional medical treatments. The most 
frequent users are educated, upper income White Americans in the 25 to 49 year age range” 
(Youngkin & Israel, 1996, p. 39). Because patients are seeking newer, unconventional 
treatments for common health care concerns, nurses must embrace the study of safe, 
complementary and alternative treatment methods. Therefore, the purpose of this study was 
to determine if the use of supplemental zinc would decrease the incidence of vaginitis in 
women prone to recurrent infection.
CHAPTER 2
CONCEPTUAL FRAMEWORK AND LITERATURE REVIEW
Conceptual Framework 
Nursing Theory - Neuman's Systems Model
Basic theory. The Neuman’s Systems Model ( 1993) was the theoretical framework 
for this thesis. The model can best be explained by using a diagram consisting of several 
concentric circles (see Figure 1). The inner circle is the “basic structure” and represents 
the individual, family, or a system. The basic structure has several common factors 
including: normal temperature range, genetic structure, response pattern, organ strength or 
weakness, and knowns or commonalties (a common range of normal characteristics and 
responses).
The next in the series of circles are the “lines of resistance”. These lines represent 
the body’s defenses that are involuntarily activated when a stressor invades the normal line 
of defense. They attempt to stabilize the client to return to the normal line of defense 
(Neuman, 1993).
The “normal line of defense” is the next outer circle. It represents the normal 
wellness level, or what the client has become. It is a result of the client’s previous 
interactions with environmental stressors, or more simply, her coping skills. It is the 
standard from which deviances from wellness can be judged (Neuman, 1993).
The outermost concentric circle is the “flexible line of defense”. It represents a 
protective buffer for the client’s normal state. It serves to prevent an invasion of stressors.
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Figure 1. Diagram of the Client System. From "The Neuman Systems Model," by 
B. Neuman, 1989, p. 28. Copyright 1989 by Appleton & Lange. Used with permission of 
the author.
This line can be thought of as accordion-like. The further away it is from the normal line of 
defense, the stronger it is. This line varies easily and is affected by nutrition, exercise, 
mental, physical, and spiritual health (Neuman, 1993). Definitions of Neuman’s paradigm 
concepts are listed below. Application of each concept to the proposed study is clarified.
Concepts. Neuman defines her paradigm concepts as:
1. Person - a composite of five variables: Physiologic, psychologic, sociocultural, 
developmental, and spiritual. Zinc supplementation is proposed to affect the physiologic 
variable.
2. Environment - has internal and external components. This can be thought of as 
the vaginal ecosystem.
3. Health - Varying degrees of harmony and balance between internal and external 
environment through a process of interaction and adjustment. Zinc may affect the balance 
of health by strengthening natural killer cell activity in the vagina.
4. Nursing - Primary goal is retention, attainment, or maintenance of client stability 
(Fawcett, 1995). The goal for nursing could be the vagina’s ecological or physiological 
stability.
Assumptions. Neuman outlined ten basic assumptions inherent in the Neuman 
Systems Model (Fawcett, 1995). For the purpose of this paper, the following will be 
defined:
1. Though each client is unique, each system is a composite of common known 
factors or innate characteristics within a normal, given range of responses, contained within 
a basic structure.
2. Many known environmental stressors exist. Each differs in its potential for 
disturbing a client’s usual stability level, or normal line of defense. Particular client 
variables (in this study the physiologic variable), can affect the degree to which a client is 
protected by the flexible line of defense against a possible reaction to a stressor.
3. Each client, over time, has evolved a normal line of defense. This line varies for 
each individual. Some people are more resistant than others.
4. When the cushioning accordion-like effect of the flexible line of defense is no 
longer capable of protecting the client against an environmental stressor, the stressor breaks 
through the normal line of defense. The interrelationships of variables - physiological, 
psychological, sociocultural, developmental, and spiritual - determine the nature and degree 
of the system reaction to the stressor.
5. The basic structure is a dynamic composite of the interrelationships of the five 
variables. Wellness moves on a continuum of available energy to support the system in its 
optimal state.
6. Implicit within each client system is a set of internal resistance factors known as 
lines of resistance, which function to stabilize and return the client to the usual wellness level 
(normal line of defense).
7. Primary prevention relates to general knowledge that is applied in client 
intervention and reduction of risk factors associated with stressors to prevent possible 
reaction. This would include client education for basic vaginal hygiene.
8. Secondary prevention relates to symptomatology following a reaction to 
stressors, and treatment to reduce their noxious effects. This would include treatment of a 
vaginal infection.
The Neuman’s System Model has a unique focus on the wellness of the client in 
relation to environmental stress and reactions to stress (Fawcett, 1995). It allows easy 
conceptualization of how optimal nutrition, including zinc supplementation, could strengthen 
the body’s resistance to recurrent vaginal infections.
Vaginitis Theory
To conceptualize how zinc may affect the vagina’s resistance to inflection, the author 
developed a diagram of the vagina and its ecosystem patterned after Neuman’s Model 
( 1989) (see Figure 2). In the author’s diagram, Neuman’s basic structure represents the
vagina, which includes a number of basic factors including normal temperature range, 
genetic structure, response pattern (to stressors), and organ strength or weakness (skin 
integrity, general health of woman).
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Figure 2. Vaginal Ecosystem Based on Neuman's Systems Model
Neuman’s lines of resistance represent the vaginal ecosystem (vaginal microecology 
system). The vaginal ecosystem contains many microorganisms that stabilize the vagina 
and attempt to return the vagina to its normal state. Lactobacilli is the dominant organism 
present in the normal vaginal ecosystem. These lactobacilli produce hydrogen peroxide 
which keeps the vaginal pH acidic and prevents overgrowth of bacterial pathogens (Sobel, 
Cook, & Redondo-Lopez, 1991). Lactobacillus acidophilus is thought to maintain 
ecological control in the vagina by competing with other organisms for adherence to the 
vaginal wall, producing protein inhibitors with antimicrobial properties and stimulating the 
immune system (ReDondo-Lopez, Cook, & Sobel, 1990).
When the vaginal ecosystem is dismpted either by a change in the vaginal flora or a 
change in the host tissue, vaginitis can occur (Overman, 1993). Changes in the normal flora 
can be due to age, hormone status, excessive douching, pregnancy, influence of drugs 
(especially antibiotics), intrauterine device use, frequent intercourse, new sex partner, or a 
compromised immune status (Kent, 1995; Ament & Whalen, 1996; Star, 1995; Tobin,
1995). When the normal flora are altered, pathogenic bacteria flourish (Kent, 1995). T 
cells also exist in the vaginal vault and are responsible for attacking foreign organisms. A 
logical conclusion then is that maintaining a healthy vaginal ecosystem is an important 
factor in preventing vaginal infections.
Changes in the vaginal ecosystem can also be due to stress. Stress results in large 
amounts of both adrenal and glucocorticoids being released into the blood stream (Cataldo, 
DeBruyne, & Whimey, 1995). “One of the most significant effects of stress-induced 
secretion of glucocorticoids is seen in immunologic function. Excessive glucocorticoids 
produce anti-inflammatory effects. Glucocorticoids also inhibit the release of histamine and 
other kinnins, thus limiting the physiologic cascade of events involving the inflammatory 
response. The result is anti-inflanmu^on and increased susceptibility to infection” (Sikes, 
1992, p. 385).
The normal line of defense represents the normal state of the vagina. This is 
affected by the general health and well being of the woman. For instance diabetes, AIDs, 
autoimmune disorders, and a high-stress lifestyle can make a woman more prone to 
recurrent vaginal Infections.
The flexible line of defense is a protective buffer and acts to prevent invasion of 
stressors. The flexible lines of defense are the interrelationships of physiological, 
psychological, sociocultural, developmental, and spiritual variables. These variables 
determine how susceptible a woman will be to stressors and also affect the balance of the 
vaginal ecosystem. Because this line is affected by nutrition (physiologic variable), zinc 
supplementation may strengthen the flexible line of defense.
In summary, Neuman’s Model (1989) and the author’s vaginitis theory are 
comprised of 4 components. For the purpose of this study, Neuman’s basic structure 
represents the vagina. Neuman’s lines of resistance represent the vaginal microecology or 
vaginal ecosystem. Neuman’s normal lines of defense are perceived as the normal state of 
the vagina. Neuman’s flexible lines of defense remain unchanged as the interrelationship of 
the five variables stated above.
Review of Literature 
This section reviews several studies that have linked zinc deficiency to recurrent 
vaginal infections. The studies have focused on candidiasis, trichomoniasis, and Human 
Papillomavirus. The candidiasis study measured plasma and tissue concentrations of zinc, 
while the trichomoniasis study focused on treatment with zinc douches. Several studies 
have been done on the use of topical zinc in wound healing that suggest positive results.
Zinc oxide has long been used as an over the counter treatment for and prevention of diaper 
rash, athlete’s foot, and sunburn. The researcher has not found any studies involving oral 
zinc supplementation as a prevention modality for vaginitis.
Zinc
Zinc properties. The mineral, zinc, plays an important role in the formation of 
protein in the body and thus assists in wound healing, blood formation, and general growth 
and maintenance of all tissues. Zinc is a component in many enzymes and is, thusly 
involved in most metabolic processes (USDA, 1990). Another property of zinc, which has 
been hypothesized to play a role in normal physiological function, is zinc’s capacity to 
stabilize membranes. This effect has been observed where zinc protects against various 
inducers of hemolysis such as bacterial toxins (Walsh, Sandstead, Prasad, Newbeme, & 
Fraker, 1994).
Delayed wound healing is a sign of moderate zinc deficiency. Recent studies show 
that a mild or marginal deficiency of zinc in humans is characterized by decreased natural 
killer cell activity and alterations in T cell subpopulations (Walsh et al.).
Zinc is a relatively safe mineral. Doses up to 6 times the Recommended Daily 
Allowance (RDA) are considered nontoxic in the healthy individual (Walsh et al.). Taking 
more than 100 mg a day of zinc for extended periods of time could result in problems such 
as depressed immune function and imbalances of copper. The use of high doses of zinc for 
longer than seven days at a time is not recommended (Herb Research Foundation, 1997).
The US RDA of zinc is 15 mg for males, 12 mg for females, and 15 mg for 
pregnant women (Walsh et al.). Studies show that many US adults get only 9.9 mg a day, 
and typically women average only 8.1 mg per day (American Zinc Association, 1997).
The cost of oral zinc supplements averages $5.(X) for 100 capsules (30 to 50 mg) or 
$ 1.50 per month, significantly less than the average $ 15 for over the counter W C  
treatments. A rare side effect is mild gastric distress. Taking the capsule with food can 
alleviate this.
Zinc toxicity. The average US citizen is at far greater risk of becoming zinc 
deficient than experiencing adverse health effects as a result of exposure to high zinc levels. 
Determining what effects excess zinc has on immune function is more problematic because
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exposure to such levels is rare, and available literature is limited (Walsh et al.). A 1984 
study suggests evidence that excessive zinc intake is toxic to the immune system. In this 
study, 11 adult males were given 3(X) mg of elemental zinc daily for 6 weeks. This level is 
20 times the RDA. This study is considered to have several flaws. Because high levels of 
zinc intake can cause copper deficiency, a major flaw in this study was the failure to assess 
serum copper levels in the study subjects. Another flaw concerns the measures used to 
assess immune status. Results of this study showed a depressed proliferative response of 
lymphocytes, yet no change in the absolute number of lymphocytes and T and B cells. Also 
noted was a reduction in the ability of phagocytic bacteria (Walsh et al.).
A second study involved giving elderly subjects 440 mg of zinc sulfate a day for one 
month. This study found that high levels of zinc intake had no adverse immunological or 
physiological effects on the elderly (Walsh et al.).
The major consequence of long-term ingestion of excessive zinc supplements is 
induction of secondary copper deficiency caused by competition between these elements for 
intestinal absorption. Levels of zinc supplements as low as 45 mg per day have negatively 
influenced copper status (Severus, Oepen, & Stoll, 1996). Long term zinc supplementation 
in excess of 150 mg per day has also been reported to result in low high density lipoprotein 
(HDD levels, gastric erosion, and depressed immune function (King & Keen, 1999). 
Chronic zinc toxicity is characterized by gastric problems, hypocupremia, and reduced HDL 
cholesterol (The Herb Research Foundation, 1997).
“Acute, high level exposure to zinc compounds can produce respiratory and 
gastrointestinal toxicity. However, these effects are largely self-limiting and require only 
modest medical attention.” (Walsh et al., p. 34). Most exposures at these levels have been 
through inhalation of smoke bombs or chronic exposure to fumes that are byproducts of 
welding. Signs of acute zinc toxicity include: gastric distress, dizziness, and nausea.
Calcium and zinc absorption. Calcium supplementation at levels of 15(X) mg per 
day has been shown to decrease zinc absorption (Tufts University Health & Nutrition
11
Letter, 1997). In 1997, Wood and Zheng investigated the effects of calcium 
supplementation on zinc absorption and balance in 18 relatively healthy, postmenopausal 
women aged 59-86 years. All subjects received a standardized diet of typical foods 
supplying 17.6 mg of zinc, and 890 mg of calcium during a 36 day period. The zinc 
balance study was divided into three, 12 day experimental periods. In two of the three 
cycles an additional 468 mg of calcium was added to the participant’s diet. Net zinc 
absorption and zinc balance were significantly reduced by approximately 2 mg per day 
during both high calcium treatment periods (p < 0.05). Measurements were obtained from 
urine samples and fecal specimens. The researchers stated that “The mechanism through 
which high calcium diets influence net zinc absorption is poorly understood’’ (Wood & 
Zheng, 1997, p. 1808).
Zinc and the common cold. Several studies have been done using oral zinc 
gluconate lozenges (23 mg) to reduce the length and severity of common cold symptoms.
At least eight studies have been performed. Of these studies, four found that zinc 
supplementation was beneficial, and four found that it was not (Jackson, Peterson, & Lesho 
1997). The average dose of zinc gluconate supplementation in those studies was 23 mg 
every 2 hours while awake for 7 - 10  days. That is an average of 184 mg daily.
Immunopathologv of zinc deficiencv. Studies on dietary zinc deficiency on the 
immune function of rodents represents the best developed paradigm regarding the effects of 
a nutritional deficiency on host defense systems. These studies indicate that zinc is 
essential to maintaining the integrity of the immune system (Walsh et al.). Information 
gathered to date indicates that a 30 day period of suboptimal intake of zinc in the young 
adult mouse, which produced a 20 to 25% weight loss, reduced the thymus to a quarter 
normal size and depleted the lymphocytes and macrophages in the spleen 50 - 75% (Walsh 
et al.). The thymus gland has a profound influence on overall immune system response in 
individual cells and blood and lymph (Scheer, 1998). Antibody mediated responses to both 
T-cell dependent and T-cell independent antigens were reduced 50 to 70%. Delayed-type
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hypersensitivity skin reactions, and the function of natural killer cells were also significantly 
reduced in zinc deficient mice (Walsh et al.). Antibody mediated responses are key to 
immune defense against a variety of pathogens, so such reductions explain the increased 
incidence of infection observed in zinc-deficient subjects (Walsh et al.).
Zinc deficiency can lead to many complications, including reduced immune function 
(American Zinc Association Newsletter, 1997). “Zinc deficiency is associated with 
depression of a number of cellular immune functions, including delayed-type hyper­
sensitivity reactions, T-helper cell activity, development of cytotoxic T cells, natural killer cell 
activity, and mitogen-induced T-lymphocyte proliferation” (Edman, Sobel, & Taylor, 1986, 
p. 1084).
Edman et al. (1986) state that zinc deficiency has been demonstrated to reduce the 
immunity of inbred strains of mice to infection with C. albicans, while zinc excess or 
sufficiency was a protective factor against Candida. In theory then, correcting a zinc 
deficiency would help maintain a normal colonization of lactobacilli in the vagina.
Zinc deficiencies result in decreased antibodies and lymphocytes, leading to 
impaired body fluids and cell-mediated immunity, as well as an increased susceptibility to a 
variety of infections (Scheer, 1998). Deficient zinc intake can profoundly depress both T 
and B cell function. Depression of B and T cell formation is manifested as a progressive 
increase in infections with opportunistic micro-organisms especially Candida albicans and 
other fungi (Walsh et al.). Zinc is required as a cofactor for at least 70 different enzymes, 
some of which are found in lymphocytes and are necessary for their function. Several 
immunologic factors have been proposed to be associated with recurrent W C . Women 
with recurrent W C  have been found to have reduced antigen-specific-T-lymphocyte 
reactivity (Nyiqesy, 1997).
Vaginitis
The pathophysiology of vaginal infections, both Candida (yeast) and bacterial, has 
long been recognized as the disruption in the normal vaginal flora. The vaginal environment
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is a dynamic and a delicate ecosystem (Mardh, 1991). Normal vaginal pH is 3.8 - 4.2. 
Normal vaginal flora consists of yeast, bacteria, and hydrogen-peroxide producing 
lactobacilli. Lactobacilli, as stated earlier, are thought to maintain écologie control of the 
vaginal ecosystem.
Bacterial vaginosis. BV is a major disruption in vaginal flora characterized by a 
massive overgrowth of vaginal anaerobes, and the disappearance of Lactobacillus species, 
especially those that produce hydrogen peroxide (Sobel, 1997). The relative lack of 
normally occurring lactobacilli alters the ecosystem of the vagina (or the lines of resistance), 
allowing anaerobes to predominate and producing metabolic by-products that raise the pH 
level of the vagina. Research to date has not clarified the cause of the microecologic shift 
resulting in BV (Overman, 1993). Amines, the end products of anaerobic metabolism, 
produce a fishy smelling discharge that is the hallmark of BV (Star, 1995).
Vulvovaginal candidiasis. Yeast infection or vulvovaginal candidiasis (W C ) is an 
upset in the homeostatic balance (normal line of defense) in the vagina that leads to an 
overgrowth of the fungus yeast {Candida). Three main types of Candida affect the vaginal 
tract: Candida albicans, Candida tropicalis, and Candida glabrata. Candida albicans is the 
most common organism found. Over the counter yeast treatments kill only Candida 
albicans, not the lesser found Candida organisms. The yeast organism gains access to the 
vaginal mucosa primarily from the perianal area (Youngkin & Davis, 1994). The warm, 
moist environment of the vulva and vagina, in combination with its close proximity to the 
rectum, make it a favorable reservoir for colonization of the yeast fungus (Secor, 1997). 
Candida albicans is found in the normal (asymptomatic) vaginal flora of premenopausal 
non-pregnant women with a 11% prevalence rate (Secor). The hallmark symptom of W C  
is vulvar pruritis (Foxman, 1997).
Zinc and vaginitis. Several studies have been done using zinc treatments for the 
diagnosis of W C , trichomoniasis, or HPV. The author did not find any studies relevant to 
zinc and BV.
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The first study reviewed evaluated the effects of potential risk factors such as HPV 
16 and nutritional status on the course of cervical dysplasia. Liu, Soong. Alvarez, & 
Butterworth (1995) found that women who were HPV 16 positive and had high levels of 
plasma zinc were less likely to develop cervical dysplasia than those without high levels of 
plasma zinc were. The study involved 206 women in Birmingham, Alabama. With the use 
of data of four repeat evaluations of dysplasia at an interval of 2 months, specific 
relationships between HPV-16 infection, plasma retinol and zinc levels, and dysplasia 
progression were evaluated through longitudinal data analysis of generalized estimating 
equations.
Andrews, Mylvaganam, and Yule, physicians from Norway and the United 
Kingdom, undertook a study in 1994 involving resistant strains of Trichomonas vaginalis, 
Tritrichomonas foetus, and Giardia intestinaiis. The activity of bacitracin with and without 
the addition of zinc on the resistant strains was studied using isolates in aerobic and 
anaerobic conditions on culture plates. Minimum Lethal Concentrations of bacitracin alone 
against Trichomonas vaginalis were 1500 - 2500 iu/mL. By adding zinc to the bacitracin 
the Minimum Lethal Concentrations needed to destroy T. vaginalis dropped to 250 - 400 
iu/mL. The primary action of bacitracin zinc is thought to be directed at the bacterial cell 
wall. The activity of bacitracin against Trichomonas was enhanced 5 -1 0  times with the 
addition of zinc. This was true in both aerobic and anaerobic culture conditions and was 
equally effective against isolates that were sensitive or insensitive to metronidiazole 
(Andrews, Mylvaganam, & Yule, 1994).
The next study reviewed involved four patients with a 4 month to 4 year history of 
culture-positive symptomatic trichomoniasis who had received a variety of therapies before 
referral. The patients selected had documented evidence of recurrent symptomatic 
trichomoniasis unresponsive to repeated courses of conventional therapy (metronidiazole). 
Another criteria for inclusion in the study was evidence that the chronic recurrence was not 
due to reinfection fiom an infected partner. The patients were instructed to douche with 25
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mL of zinc sulfate solution in 250 mL of distilled water. After douching, they inserted a 
500 mg metronidiazole suppository vaginally. This therapy was given twice a day for the 
first week, and then gradually tapered off over 5 months. At a review 2 to 5 months after 
therapy, all patients remained asymptomatic and culture negative (Houang, Ahmet, & 
Lawrence, 1997). The exact role of zinc sulfate douching is not known, but the combination 
of zinc and metronidiazole therapy achieved a cure in these patients at a dosage that had 
failed before, when metronidiazole was used alone (Houang, et al., 1997).
Another case study involved a woman with trichomoniasis who failed to respond to 
high dose metronidiazole, over a 4 month time frame. At completion of this therapy she was 
still found to be culture positive. She was admitted for intravenous (IV) metronidiazole 
therapy, 500 mg three times a day for 5 days. Within one week of IV therapy, urethral and 
vaginal cultures were positive for trichomoniasis. At this stage, plasma and urinary zinc 
levels were measured. Her plasma zinc level was 9 (normal 12 - 20), and urinary zinc level 
was 3 (normal 4 -12). She was prescribed zinc sulfate, 220 mg orally twice a day for 3 
weeks. Her plasma zinc level rose to 12. After 15 months of recurrent infection, this patient 
was culture negative for four months after treating her low plasma zinc level (Willmott, Say, 
Downey, & Hookham, 1983).
A specific study on zinc and candidiasis took place in 1985. Drs. Edman, Sobel, 
and Taylor evaluated the relationship between zinc status and recurrent vaginal candidiasis. 
Twenty-nine subjects with at least 3 documented episodes of acute Candida vaginitis in the 
previous 12 month period comprised the experimental group. The control group consisted 
of 20 women who had never been diagnosed with vaginal candidiasis. The two groups were 
matched for age, race, and parity. None of the subjects were pregnant, postmenopausal, or 
had any chronic health conditions. Seven subjects with recurrent vaginitis (24.1%) were 
taking zinc-containing supplements, while five control subjects (25%) were taking zinc- 
containing supplements. Dietary zinc intake was assessed based on 3 day food
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consumption records. The results suggested that dietary zinc intake between the two groups 
was not statistically significantly different (p = 0.190).
Plasma zinc measurements were then obtained from both groups. The mean plasma 
zinc concentration in the recurrent vaginal candidiasis group was 87 pg/dl in zinc- 
supplemented women and 79 p,g/dl in non-zinc-supplemented women. In the control group, 
mean plasma zinc levels were 95 pg/dl in the zinc-supplemented women, and 91 pg/dl in the 
non-zinc-supplemented women. The mean plasma zinc concentration was significantly 
lower in women with recurrent vaginitis not receiving zinc supplements (79 pg/dl) when 
compared with control nonsupplemented women (91 pg/dl.) (p = 0.015). Comparison of 
the women in both groups who were receiving zinc supplements showed the plasma 
concentration was lower in women with recurrent infection (87pg/dl), than in the control 
group (95 pg/dl), but this was not statistically significant (p = 0.52) (Edman et al., 1986).
The results of this study suggest that women in the group not receiving zinc with 
recurrent vaginal candidiasis had significantly lower mean plasma zinc levels than women 
who had never had an episode of Candida vaginitis. Limitations of this study include the 
fact that the zinc supplements were not standardized. There is no indication of how many 
milligrams of zinc the women were taking or whether it was the same type of zinc (i.e., zinc 
gluconate, zinc acetate, etc.) (Edman et al.).
Edman et al. suggest that "additional studies are required to correlate zinc status in 
women with recurrent vaginal candidiasis. Controlled longitudinal studies are necessary to 
correlate the effects of zinc supplementation with immune status in susceptible women and 
to evaluate the effects of zinc supplementation on the clinical recurrence rate of Candida 
vaginal infection. In light of the available data correlating acquired zinc deficiency with 
reduced T-lymphocyte function, a parameter known to be impaired in women with recurrent 
vaginal candidiasis, zinc deficiency may be a contributing factor in some women with 
recurrent vaginal candidiasis” (1986, p. 1085).
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Following publication of the previously reviewed study, Bohler, Meisinger, Klade 
and Reinthaller ( 1994) undertook a study measuring zinc levels of serum and cervicovaginal 
secretions in women with recurrent W C . Twenty-one women with at least three 
documented episodes of W C  within the previous 12 months, and 15 women without W C  
as a control group were investigated.
Results showed no significant difference in the mean plasma zinc concentrations 
between the recurrent W C  group ( 109 ng/dl) and the control group (107 |ig/dl). 
Measurements of cervicovaginal secretions showed 30.2 pg/dl of zinc in the recurrent W C  
group, and 29.6 |ig/dl of zinc in the control group. This difference was not significant. (No 
normal zinc values of cervicovaginal secretions have been established). While no 
confirmation of zinc deficiency in women prone to recurrent W C  was found, “controlled 
studies should help to clarify whether zinc supplementation affects clinical cure rate of 
W C "  (p. 310).
This study is limited by that fact that dietary zinc intake was not assessed. Also, it is 
not known whether any of the subjects were using zinc supplementation. It is also not 
known whether zinc levels in cervicovaginal secretions are a valid measurement in regards to 
this topic (Bohler et al.).
Summary and Implications for Study
The vaginal environment has an innate immune system (lines of resistance).
Changes in the immune system, which disturb the delicate balance of lactobacilli, can result 
in vaginitis. Zinc is known to enhance the immune system. Conversely, zinc deficiency can 
negatively impact the vaginal immune system. Correcting a zinc deficiency, by a safe, cost- 
effective method may decrease the incidence of recurrent vaginitis.
The literature points to several instances in which the use of zinc enhanced treatment 
of resistant vaginitis. Research suggests that zinc supplementation can help the body’s 
immune system response to infection. There is little data or knowledge available to nurses, 
physicians, and the general public about what preventive measures can be taken to reduce
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the incidence of recurrent vaginitis. Zinc supplementation alone has never been studied in 
relation to prevention or treatment of recurrent vaginal infections. Nursing could certainly 
benefit from this study if a positive correlation is shown. Although this was a small study, it 
provides a starting point for a more comprehensive research study in the future.
Purpose/Hypothesis
Maintenance of a healthy vaginal microecology is vital in the prevention of vaginitis. 
Because zinc deficiencies can lead to impaired immune functioning, correcting a presumed 
zinc deficiency may help maintain a normal colonization of lactobacilli in the vagina, thereby 
reducing the incidence of recurrent vaginitis. The purpose of this study was to evaluate the 
effect of oral zinc supplementation on the recurrence of vaginitis (either W C  or BV) in 
women ages 18-45 that are prone to recurrent vaginitis.
The research hypothesis stated women, between the ages of 18 - 45 with recurrent 
vaginitis who take 30 mg of oral zinc supplementation, will have fewer cases of vaginitis 
than women who do not supplement during a six month time frame.
Definition of Terms
Recurrent vaginitis is defined as two or more episodes of clinician-identified 
vaginitis in a 6 month time frame.
Oral zinc supplementation for this study is defined as 30 mg of zinc gluconate daily 
in capsule form.
Presence of clinician diagnosed vaginitis was evaluated during pre-determined study 
intervals and/or as a result of patient request. Evaluation included a vaginal pH, a 
microscopic saline wet mount, and a potassium hydroxide (KOH) whiff test. Three types 
of vaginitis were assessed: Candida, bacterial vaginosis, and mixed infections (W C  and 
BV).
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CHAPTERS
METHODS
Research Design
This was an experimental, double-blind study. One group of women, the control 
group, was given an oral placebo to take on a daily basis. The other group, the study group, 
was given a zinc supplement to be taken daily. Comparisons were made between the two 
groups to determine if zinc supplementation reduced the incidence of recurrent vaginitis. 
The independent variable in the study was zinc supplementation. The dependent variable 
was the incidence of vaginitis. The research assistant used a coin toss method to determine 
which group the first participant would enter. Thereafter participants were placed in 
alternate groups.
Sample and Setting
Sample
Women were identified through visits over the last 12 months to the researcher’s 
private practice. They were asked to voluntarily participate in the study. Selection criteria 
limited participation to non-pregnant, sexually active females, between the ages of 18 - 45. 
Participants had no history of diabetes, were not pregnant, were not on any daily 
medications other than contraceptives, anti-depressants, non-steroidal anti-inflammatory 
drugs, antacids, or anti-hypertensives (in people with normal kidney function), were pre­
menopausal, and were not intrauterine device (lUD) users. lUD use is thought to affect 
normal vaginal flora (Star, 1995). Criteria for exclusion included conditions known to 
influence zinc status such as inflammatory diseases, recent myocardial infarction, recent 
surgery, chronic debilitation or malabsorption states, chronic infections other than vaginitis.
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and corticosteroid use (Edman et al., 1986). Chronic health conditions may affect 
absorption and retention of zinc in the body. Therefore, women with chronic health 
conditions were excluded from the study.
Participants were consumers who had been seen in the researcher’s practice in the 
past year and found to have had at least two episodes of clinician diagnosed bacterial 
vaginosis or yeast infection, or mixed vaginitis in a previous 6 month time frame.
Setting
The study site was a private practice obstetrics and gynecology office in a rural 
community in a Midwestern state. This was a free standing, one floor, handicap accessible 
building. The facility includes six modem exam rooms, and a lab where microscopies were 
performed.
Instruments
Instruments of measurement in this study were the wet mount, the potassium 
hydroxide (KOH) whiff test, the pH nitrazine paper test to diagnose vaginitis, and the 24- 
hour diet recall to estimate average daily zinc intake. The researcher also occasionally used 
a laboratory culture if it was deemed necessary. “If a wet mount has a questionable result, a 
laboratory culture can help confirm or deny the presence of vaginal pathogens’’ (Sobel et 
al., 1998). Anyone unresponsive to treatment received a urogenital culture. “Fungal culture 
results will corroborate microscopic findings and are more sensitive than microscopic 
examination to detect yeast” (Nyirjesy, 1997, p. 19).
24-Hour Diet Recall
To estimate the subject’s dietary zinc intake, the standard 24-hour diet recall method 
was used. The study participants were asked to identify how many servings of all foods 
they consumed in the last 24 hours, providing this was a normal intake for them. None of 
the participants reported that the previous 24 hour time period had been atypical. This recall 
determined if the subject’s intake fell within the average range of zinc consumption (8.1 mg 
daily). Dietary recall was documented on the subject’s second visit, and was administered
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by the researcher. Participants were asked to estimate the size of their servings and given 
visual aids of a 2 cup measure, a I cup measure, and a one-half cup measiue. Their average 
zinc consumption was then estimated using information obtained from Bowes & Church’s 
food values of portions commonly used (Pennington. 1994).
Diagnosis of Vaginitis
Patient historv. The patient history for diagnosing vaginal infections included a 
description of vaginal symptoms with duration, sexual activity, current medical conditions 
and medications (including use of herbs, vitamins, and over the counter preparations), 
contraceptive methods (including use of condoms, spermicides or treated condoms), history 
of STDs or vaginitis, hygiene habits, recent change in detergents or soaps, recent episodes 
of douching, a description of aggravating or alleviating factors, family history of diabetes, 
social history, and a menstrual history (Plourd, 1997; Star, 1995).
Diagnosis of BV included an accurate and thorough patient history, bimanual pelvic 
examination, pH test, wet mount, and KOH whiff test (Plourd, 1997; Association of 
Professors in Gynecology and Obstetrics [APGO], 1996). Diagnosis of BV is made by the 
presence of 3 of the following 4 objective findings: abnormal discharge, elevated pH, amine 
odor, and the presence of clue cells by microscopy (Star, 1995). The wet mount/KOH slide 
of a patient with BV will have an obvious lack of lactobacilli, clue cells, WBCs, and may 
have high concentrations of anaerobic bacteria such as Bacteroides, Mobiluncus, and 
Gardnerella vaginalis. How this imbalance of lactobacilli and anaerobic bacteria causes 
BV is not yet known (Selleck, 1997). Although unreliable alone for diagnosis, subjective 
symptoms of BV include a mild to moderate discharge with a fishy odor (particularly worse 
after intercourse), and mild vulvar irritation or burning.
Diagnosis of W C  included an accurate and thorough patient history, pelvic exam, 
pH test, and wet mount with KOH. A vaginal culture is also helpful when patients report 
symptoms of W C , but have a negative wet mount. W C  does not raise vaginal pH. 
Subjective symptoms of W C  include vulvar itching and an increased white clumpy or
22
flocculent discharge. The patient with W C  may also complain of dyspareunia, burning 
with urination, and soreness (Sobel, Faro, Force, Foxman, Ledger, Nyirjesy, Reed, & 
Sununers, 1998).
Physical exam. Physical examination to diagnose vaginal infections included a 
close inspection of the vulva, vaginal walls and cervix for the presence of lesions, discharge 
or erythema. The specula was lubricated with a small amount of warm water only as KY 
jelly can affect pH readings. The vaginal discharge was examined for color, consistency, 
odor, whether it was coming from the cervix, and if it was adherent to the vaginal walls. BV 
discharge Is usually thin, homogenous, white, gray, adherent, malodorous, flocculent, and 
sometimes increased (APGO, 1996). Signs of BV include: elevated vaginal pH, mild to 
moderate milky discharge, with a fishy or amine odor.
Objective signs of W C  are vulvar edema and erythema. The vulva and vagina are 
often red, inflamed, and excoriated due to scratching. The uterus, adnexal, and rectovaginal 
exam are within normal limits (Star, 1995). A vaginal discharge is common, and tends to be 
thick, clumpy and white (Youngkin & Davis, 1994). Wet mount will show normal flora, 
blastospores, and 40% - 50% of patients will be positive for pseudohyphae on the saline 
side. On the 10% KOH side, the positive pseudohyphae will increase to 60% - 90% of 
patients. See discussion immediately following for description of preparing a wet 
mount/KOH prep. There will also be a decreased lactobacilli population (Sobel, 1997). 
WBCs are present in mixed infections, as well as both yeast hyphae and clue cells.
Wet mount/KOH prep. A wet mount involves examining vaginal discharge under 
the microscope. The wet mount is considered to be the key diagnostic test for BV (Selleck, 
1997). EYeparation of a wet mount involves preparing two slides: one with 2 drops of 
normal saline, the other with 2 drops of a 10% - 20% solution of KOH (potassium 
hydroxide). Two separate swabs of vaginal secretions from the vaginal walls are obtained 
using a clean wooden spatula. Use of Dacron or cotton swabs was avoided because the
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fibers may sometimes be mistaken for yeast hyphae on microscopic examination (Selleck, 
1997).
The first sample of vaginal secretions was applied on the saline slide using two or 
three rotations of the spatula to ensure a dilute sample. The second sample of vaginal 
secretions was applied to the KOH slide. Ten to fifteen rotations of the spatula in the KOH 
was used to assure a fairly concentrated sample (APGO, 1996). A “whiff test” with the 
KOH slide was performed immediately. The KOH-vaginal fluid mix was sniffed to assess 
for a strong, amine odor. The presence of this odor occurs in abut 50% - 75% of all 
patients with BV (APGO, 1996).
The slides were then examined within 5 minutes of preparation under both low 
power (4x - lOx objective) and high power (> 40x objective) settings. At low power, the 
saline slide was observed for the presence of white blood cells (indicative of Trichomonas), 
mobile pear-shaped organisms with a tail (Trichomonas), yeast buds or pseudohyphae, and 
lactobacilli (long, rod-shaped). The KOH sample was examine for clue cells and 
pseudohyphae. A clue cell is a vaginal epithelial cell with clumps of bacteria adherent to the 
edges. At least 20% of observed epithelial cells should be clue cells to be of diagnostic 
significance for BV (Sobel, 1997). “A normal vaginal pH, and a negative whiff test 
eliminate 95% of all cases of BV” (Sobel, Personal Communication, 1998). A normal 
vaginal slide would contain only vaginal epithelial cells and lactobacilli.
Wet mount interpretation depends on the skill of the clinician. The researcher has 
been preparing and interpreting wet mounts for several years. She has also had two training 
sessions at Wayne State University in 1998 with Dr. Jack Sobel, an internationally known 
expert in the field of vaginitis. The researcher was the only clinician interpreting the wet 
mounts, thus consistency was maintained.
Nitrazine paper pH test. The pH test provides a quick indication of what type of 
infection the patient may have. A pH greater than 43  can indicate BV. Candida (yeast) 
infections usually result in a pH of less than 4.5 (Sobel, 1997). Douching, water, recent
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intercourse, lubricants, cervical mucous, semen, spermicides, condoms, menstraal secretions, 
and amniotic fluid can all result in altered pH (Sobel). The subjects were asked to refrain 
from intercourse for 24 hours before their exams. They were questioned about recent 
intercourse prior to their exams and all subjects denied this. To obtain a pH specimen, the 
posterior and lateral fomices of the vagina were swabbed and the specimen was placed on 
the pH paper. The cervical os was avoided due to cervical mucous lowering the pH value. 
Evaluation of the pH level was done by comparing the color of the pH test strip to the color 
key on the test strip container (APGO, 1996).
Procedure
The researcher kept a record for the past 12 months of women who presented to her 
with recurrent vaginitis (2 or more infections in a six month time frame). All women 
presenting with complaints of a vaginal infection underwent a physical exam, patient history, 
KOH whiff test, wet mount, and pH test. Based on the researcher’s diagnosis, they were 
treated with an appropriate medication (see Appendix F for office protocol for treating 
vaginitis).
The women in the practice who had been identified as having recurrent vaginitis 
were contacted by telephone by the researcher or the research assistant. The women were 
invited to participate in the study. A letter that explained the procedure in more detail was 
sent to the women who stated they were interested in participating in the study. The women 
were scheduled a 30 minute appointment with the researcher to review the consent form in 
detail, answer any questions, receive their initial exam (which included a patient history, 
physical exam, wet mount, pH test, and KOH whiff test), and receive their supplements or 
placebos.
After selection and informed consent were obtained, subjects were randomly placed 
in either the study group or the control group by the research assistant using a coin toss 
method initially, and then placed in alternating groups.
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The zinc capsules were removed from their original packaging by the research 
assistant and placed in plain bottles obtained from a pharmacy labeled “B”. The placebo 
capsules were prepared by a local pharmacy and placed in plain bottles labeled “A”. The 
placebos were gelatin capsules filled with com starch. The research assistant had exclusive 
knowledge as to which bottles contained the zinc, and which bottles contained the placebos. 
The researcher did not have access to any information that revealed which capsule was the 
zinc and which was the placebo.
Each participant was designated an individual sheet in the researcher’s notebook to 
carefully track all data (Appendix B). This data included: age, race, name, patient 
identification number, whether they were taking capsule A or capsule B, diet recall and 
average zinc intake, any medications, vitamins, or herbal supplements they may have been on 
during the course of the study, number and type of vaginal infections, treatment used, 3 and 
6 month count of capsules, results of initial, 3, and 6 month wet mounts, KOH whiff tests, 
pH tests.
Participants were asked to present to the researcher, free of charge, once every 3 
months for a wet mount, pH test, KOH whiff test, and physical exam. Appointments were 
scheduled that were convenient for the participants. The participants were also asked to 
present at any time they had symptoms of a vaginal infection. These instructions were given 
to them in writing, and reviewed with them verbally by either the researcher or the research 
assistant. Findings of the 3 wet mounts, pH tests, and KOH whiff tests allowed the 
researcher to detect any vaginal infections that may have gone unnoticed by the subject. A 
wet mount, pH test, KOH whiff test, and physical exam at the time of vaginal symptoms 
established the diagnosis of a vaginal infection.
When subjects returned for their 3 month interval visits, they were asked to bring in 
their bottles of capsules to help determine if they were taking the capsules as directed. The 
research assistant manually emptied and counted the remaining capsules and documented 
this in her notebook. The researcher did not observe this activity. If it appeared the
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participant was not taking the capsules regularly, she was counseled by the research 
assistant. At 3 months an interim history was obtained by the researcher, as well as a diet 
recall. Questions asked were directed at any health changes, change in sex paitners, major 
life stressors (Job change, moves, divorce), or dietary changes. These data were entered in 
the researcher’s notebook.
The final 6 month visit included a physical exam, wet mount, pH test, KOH whiff 
test, and another interim history. Any change in the subject’s situation was again noted in 
the researcher’s notebook. If physical exam or patient history revealed signs or symptoms 
of a STD, appropriate follow up would have been obtained. The researcher found no 
subjects at risk for STD's by history or physical exam. No changes were implemented in 
the procedural process during the study.
In order to minimize effects on absorption from other nutrients or supplements, 
participants were instructed to take either the zinc 30 mg capsule or placebo at bedtime with 
a food from an approved food list (see Appendix C). Foods containing calcium or iron 
have the greatest effect on altering zinc absorption. Therefore, women were asked to take 
their vitamin, mineral, or herbal supplements in the morning. At bedtime, or at least two 
hours after meal consumption, they were instructed to take their zinc supplement or placebo 
with either a glass of water alone, or with foods that do not contain significant amounts of 
calcium or iron.
Vaginal infections can be a secondary effect of taking antibiotics. All study 
participants were, therefore, asked to report any antibiotic therapy they used during the 
course of the study. This was recorded in the researcher’s notebook. If a subject was 
found to have a vaginal infection during the study, she was offered a standard treatment (see 
Appendix F) and remained in the study. Both study groups were treated the same.
Human Subjects Protection
This study required that half the participants take 30 mg of zinc orally per day. 
There are no known risks involved in using zinc supplementation at this level (Walsh et al..
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1994). The dosage of 30 mg was chosen because it is well tolerated, there is no danger of 
toxicity, and it is readily available. This is well below the 300 mg dose where immuno­
suppression is suspected (Walsh et al.). Women were told that if they were in the placebo 
group, they were taking a gelatin capsule filled with com starch.
Subjects were assured of confidentiality and anonymity when they signed their 
consent form (see Appendix A). They were assured that participating in the study would 
not interfere with health care provided through the researcher’s office. They were advised 
of any risks (zinc can cause nausea in some subjects). The list of participant’s names was 
later destroyed for confidentiality.
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CHAPTER 4 
RESULTS/DATA ANALYSIS
Data Analysis
Maintaining a healthy vaginal microecology is an important factor in preventing 
vaginitis. Because zinc deficiencies can lead to impaired immune functioning, correcting a 
presumed zinc deficiency may help maintain a normal colonization of lactobacilli in the 
vagina, thereby reducing the incidence of recurrent vaginitis. The purpose of this 
experimental double-blind placebo study was to evaluate the effect of oral zinc 
supplementation on the incidence of vaginitis (either W C  or BV) in women ages 18-45 
that are prone to recurrent vaginitis. The statistical software program used was Minitab®. 
The level of significance was set at p = .05.
Characteristics of Subjects
Fifty-six women were initially identified as meeting the inclusion criteria for the 
study. These women were contacted by phone and asked to voluntarily participate. Forty- 
one women agreed to participate in the study. All women were Caucasian and between the 
ages of 18 - 45. All of them lived within a 40 mile radius of the researcher’s office. At 
each visit subjects were asked about specific stressors in their life, i.e.; job change, divorce, 
separation, or death in the family. None of the participants stated they experienced any of 
these stressors during the study.
Medications used by participants during the study included anti-depressants, oral 
contraceptives, Depo-Provera contraception, pain relievers, antacids, and antibiotics. Herb 
use among the participants was infrequent, however some participants reported using St. 
John’s Wort, flsh oil, cranberry extract, echinacea, and acidophilus. Only one participant in
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the placebo group reported use of acidophilus. None of the participants had experienced a 
recent birth or termination of pregnancy. None reported a change in sex partner or any 
significant changes in their diet, health status, or weight. The participant’s occupations were 
varied (e.g. accountants, waitresses, homemakers, teachers, bartenders, and clerical workers).
Participants who withdrew. Fifteen participants withdrew from the study after the 
initial visit, leaving a total of 26 participants. The women who withdrew were of similar age 
to the remaining subjects: m = 28.88 years in the placebo group (n = 8), and m = 29.83 
years in the zinc group (n = 7). The number of previous vaginal infections was similar as 
was as their vitamin and contraceptive use. Table 1 compares several characteristics of 
participants who stayed in the study with those who withdrew.
Table 1
Comparison of Participants with Those who Withdrew (N = 4H
Study Participants 
N = 26
Subjects who Withdrew 
N =  15
Age range 18-44 years 17 - 39 years
Contraceptive users 12(m = 2.2) 5 (m = 3)
Vitamin/Calcium users 10 (m = 2.6) 5(m  = 3)
Prior vaginal infections m = 2.9 m = 2.6
Potential Intervening Variables
This section will examine the characteristics of the 26 women who remained in the 
study. In order to determine if there were any potential intervening variables that were 
different between the placebo group and the zinc group, nine characteristics of the 
participants were examined. Table 2 summarizes these characteristics. It appeared there 
were no differences in the participant’s age, zinc intake, prior vaginal infection rate.
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antibiotic use, or vitamin use. However, three potential intervening variables were identified: 
compliance (number of pills missed), contraceptive use, and extra visits. One participant in 
the zinc group was found to have 9 infections and 7 extra visits, and therefore considered to 
be a potential outlier. A statistical analysis done without that subject did not change the 
results.
Table 2
Characteristics of Study Participants (N = 261
Placebo Group 
n = 11
Zinc Group 
n = 15
Age 31.6 years. 29.7 years.
Daily dietary zinc intake 6.1 mg. 5.68 mg.
Pills missed during study 18.2, 8.3,
Vaginal infections in 6 months 
prior to study
2.9, 2.9,
Extra visits for vaginal complaints 3 15
Persistent infections 1 3
Courses of antibiotics during study 4 7
Vitamin and/or calcium users 4 6
Oral contraceptive or depo-provera users 4 8
Expressed as a mean.
In order to determine if the three potential intervening variables were statistically 
significantly different between groups, a 2 sample t-test analysis was performed on each 
variable. None were found to be statistically significant. Table 3 shows the statistical data 
of these three variables.
If a woman was found to have a persistent vaginal infection during the study, a 
urogenital culture was obtained. This occurred three times in the zinc group. One culture 
was positive for E. coli and she was treated with a seven day course of cephaloxin; the other
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two confirmed a heavy growth of gardnerella and Candida albicans. A persistent vaginitis 
was found once in the placebo group; that subject had one urogenital culture confirming 
Candida albicans in a mixed infection, and another culture confirming gardnerella in a 
diagnosis of BV.
Table 3
Potential Intervening Variables
Mean SD t df P
Compliance
Placebo
Zinc
18.2
8.3
15.6
13.1
1.71 19 0.10
Contraceptive Use 
Placebo
Zinc
0.364
0.667
0.505
0.488
1.53 21 0.14
Extra Visits 
Placebo
Zinc
0.273
1.00
0.647
1.85
1.41 18 0.18
Hypothesis Testing
A summary of the incidence of vaginal infections prior to and during the study can 
be found in Table 4. In order to compare the incidence of vaginitis after the treatment (zinc 
or placebo) effect, the number of prior vaginal infections was combined with the initial visit 
data. Since no treatment had been administered at the initial visit, if participants were 
diagnosed with a vaginal infection at that time, that infection was included with the prior 
infections.
Statistical Analysis
In order to test for differences in the incidence of vaginal infections between the 
placebo group and the zinc group at post-treatment, a t-test analysis for independent means
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was performed. Table 5 shows this information. There was no significant difference found 
(p = 0.16). The research hypothesis that women between the ages of 18 - 45 prone to 
vaginal infections who take 30 mg of zinc gluconate daily would have fewer cases of 
vaginitis than women who do not take a supplement during a six month time frame was 
rejected.
Table 4
Summary of Incidence of Vaginal Infections in Participants (N = 26)
Group BV Yeast Mixed Total
Zinc (n=15) Prior Study Prior Study Prior Study Prior Study
1 Infection 2 4 1 3 3 1 6 8
2-3 Infections 8 3 3 1 2 2 13 7
< 3 Infections 2 1 2 0 0 0 4 1
Total Infections 31 14 19 5 7 6 57 25
Placebo (n=l 1) Prior Study Prior Study Prior Study Prior Study
1 Infection 1 1 2 1 1 1 4 3
2-3 Infections 7 1 2 2 0 0 9 3
< 3 Infections 1 0 I 0 1 0 3 0
Total Infections 23 3 10 5 5 1 38 9
Table 5
Statistical Analysis of Placebo Group and Zinc Group (N = 26)
Vaginitis
Episodes
Total Range Mean SD df t-value
Placebo
(n=ll)
9 (0-3) 0.82 1.06
22 1.45
Zinc
(n=15)
25 (0-7) 1.67 1.88
On further examination of data from the zinc group, it appeared there was a 
difference in the mean incidence of yeast, dropping from 19 prior to the study (m = 1.26) to 
5 following zinc supplementation (m = 0.33). A paired one sample t-test analysis
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confirmed a significant decrease in the incidence of W C  in women taking 30 mg of zinc 
gluconate daily (t = 2.23, p = 0.021).
34
CHAPTERS 
DISCUSSION AND IMPLICATIONS
Discussion
Results
The research hypothesis for this study was that women between the ages of 18 - 45 
prone to vaginal infections who take 30 mg of zinc gluconate daily would have fewer cases 
of vaginitis than women who did not take a supplement during a six month time frame. It 
was found that the overall occurrence of vaginitis between the placebo group and the zinc 
group at post-treatment was not significantly different (p = 0.16). Thus the hypothesis was 
rejected. However, a significant decrease in the incidence of W C  infections was noted in 
the zinc group (p = 0.021 ).
Per a 24 hour dietary recall, the 26 women participating in the study had a mean 
daily zinc intake of 5.86 mg, while the RDA for zinc is 12 mg per day. This group of 
women with documented recurrent vaginal infections can be classified as having inadequate 
zinc intake based on the 24-hour diet recall. It is interesting to note that the participant with 
the most documented vaginal infections ( 14 prior to and during study) had the lowest zinc 
intake (0.13 mg/day). This subject was undernourished based on her 24-hour diet recall. 
She reported consuming only one small meal that day and on typical days.
Neuman’s Model
Even though the research hypothesis was rejected, some data from the study seem to 
support the theory that zinc has impact on the vaginal ecosystem. Women in this study had 
inadequate zinc intakes and had recurrent vaginal infections. Women treated with zinc had a 
decrease in the incidence of W C . Recalling the vaginitis theory based on Neuman’s
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Model (see Rgure 2), the internal lines of resistance represent the vaginal ecosystem. Part 
of this ecosystem is T cells, which are responsible for attacking foreign organisms. Walsh, 
et al., ( 1994) stated that “Even a mild or marginal zinc deficiency in humans is characterized 
by decreased natural killer cell activity and alterations in T cell subpopulations”. Therefore, 
the lines of resistance may be weakened by inadequate zinc intake.
The flexible line of defense acts as a buffer to prevent invasion of stressors, in this 
case vaginitis, and can be affected by nutrition. A woman with good overall nutrition is 
likely to have stronger defenses against illness than a woman with inadequate or poor 
nutrition. Using zinc supplementation may help strengthen the flexible line of defense. 
There may be other factors not yet identified that can strengthen a woman's defenses against 
recurrent vaginal infections.
Inferences from Literature Review
The researcher found no significant difference in the overall vaginal infection rate 
between the placebo group and the zinc group at post-test. There was however a decrease in 
the rate of yeast infections in the zinc group from 19 to 5. One could theorize that the 
lactobacilli in the vagina have more impact on yeast infections than BV. In fact, Edman et al. 
(1986) found that zinc deficiency reduced the immunity of mice to Candida albicans, while 
a zinc excess was a protective factor.
There have been no studies done using zinc as a prevention for vaginitis. However, 
if the review of literature is re-examined, several consistencies can be found. Scheer (1998) 
stated that a zinc deficiency could lead to impaired immune function. Edman et al. ( 1986) 
found that zinc deficiency depresses a number of cellular immune functions, including T 
cell proliferation. Walsh et al. (1994) state that depression of B and T cell formation is 
manifested as a progressive increase in opportunistic infections, especially Candida 
albicans. Nyirjesy (1997) states that women with recurrent W C  have been found to have 
reduced antigen specific T-lymphocyte reactivity. All of this literature supports the theory
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that zinc deficiency reduces the T cell population in the vaginal ecosystem, thereby placing a 
woman at risk for infection with Candida albicans.
There are three documented cases of zinc being used as a treatment for recurrent or 
resistant trichomonas. Andrews et al. ( 1994) used bacitracin plus zinc, Houang et al. {1997) 
used zinc sulfate douches plus metronidiazole, and Willmott et al. ( 1983) used oral zinc 
sulfate. All three of these cases were successful at eradicating the trichomonas with the 
addition of zinc when conventional therapies had failed.
There have been prior studies on using zinc as a topical treatment for resistant 
vaginal infections and there have been prior studies on zinc deficiency and recurrent 
vaginitis. However, this is an original study on supplementing zinc in women prone to 
recurrent vaginal infections, so the researcher had no other study with which to compare 
these results.
Threats to Internal Validity
The procedure was assured validity through the use of the double-blind technique. 
Neither the researcher nor the study participant knew if the subject were taking a zinc 
supplement, or a placebo. Asking the participant to bring in her capsule bottle at the 
appropriate times to determine if she took them correctly protected internal validity. If a 
variability existed in the daily consumption of capsules, close record of this was kept in the 
researcher’s notebook and the participant was counseled.
Threats to internal validity of the study were of most concern in the area of attrition. 
It was assumed that most women who had problems with recurrent vaginitis would be 
motivated to find solutions to their problems and this motivation would help with retention 
and follow through. Women are often frustrated that the health care system has little to 
offer for prevention of recurrent vaginal infections and therefore may have been willing to 
try alternative methods of treatment or prevention. Most of the women contacted initially 
agreed to participate in the study, yet the attrition rate was high.
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It was hoped that the sample size of at least 30 participants in both the zinc and 
placebo groups would provide a margin for attrition with enough remaining numbers to 
perform meaningful statistical analyses. However, with the small sample size and the high 
attrition rate, that did not happen. Randomizing whether the participant received the zinc or 
placebo helped assure validity. Selection criteria facilitated similar subjects, and 
randomization of groups again minimized these threats. Subjects were selected based on no 
other risk factors being present.
The attrition rate for the study was 37%, or 15 of 41. Because participants were not 
required to inform the researcher nor asked why they decided not to participate, specific 
reasons cannot be quoted in all cases. Three of the participants became pregnant. Several 
who dropped cited reasons such as not remembering to take their capsules, being unable to 
follow the guidelines for taking capsules, or not having enough time to schedule the 
required visits. One participant was dropped because it was discovered that she was 17 
years old and below the age of informed consent.
The Hawthorne effect was minimized because both groups of women being studied 
received an intervention. They both took pills, and both groups came in at three month 
intervals to be examined.
History effects on the participants were minimized because they were not asked to 
change any of their current dietary or behavioral habits, and were not encouraged to make 
lifestyle changes such as changes in sexual practices. Becoming pregnant was a maturation 
threat that could not be controlled. If a participant became pregnant during the study, she 
was withdrawn. The researcher stayed in contact with the study participants throughout the 
six months. The researcher or research assistant collected all pertinent data to describe what 
happened during the course of the study (see Appendix B). Participants were offered free 
office calls for symptoms of vaginitis while they were enrolled in the study.
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T.im itafinns
This Study was limited by several factors. Small sample size was a major limitation 
(N=26). This factor placed severe limits on performing meaningful statistical analysis. 
Absence of a plasma or urinary zinc level measurement in the subjects to document zinc 
deficiency was a concern. This factor was cost-prohibitive in this study environment. 
Providing zinc supplementation at only one dosage also limited the range of this study as 
different effects may be noted at different dosages.
The study of nutrient deficiencies is a complex phenonemon. Use of the 24 hour 
diet recall gives the researcher only a small sample of a subject's true dietary intake. There 
are multiple relationships between nutrients that can affect absorption and utilization. The 
only such factor this study attempted to control was the relationship between calcium and 
zinc. Factors that were not controlled for because of the small sample size were the use of 
herbs, contraceptives, vitamins, antacids, and sexual practices.
An assumption made in this study was that participants were heterosexual and 
monogamous. No control could be made for participant's sexual partners changing sexual 
partners. Another assumption was that by supplementing zinc at 30 mg (which is over the 
RDA of 12 mg), subjects would be adequately nourished. An inadequate zinc intake may 
represent only one nutrient deficiency in a subject's diet. How other nutrient deficiencies 
may affect vaginitis has not been researched. A larger study would enable a researcher to be 
more selective or controlling in regards to some of these factors.
During the data collection process, the researcher did ask about recent intercourse 
before the physical exam as semen can alter pH readings. However, the participants were 
not questioned about recent use of douches, or sexual practices. Douching can alter pH 
readings. Oral/genital sex can increase the occurrence of BV. The participants were 
discouraged from using douches as part of the general hygiene information given to patients 
with recurrent vaginitis. However, objective measures for vaginitis may have been affected 
by the lack of documentation in regards to douching and sexual practices.
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Suggestions for Further Research
A future study with a larger sample size would be of great benefit to nursing 
research. Based on the researcher’s experience with this study, several modifications can be 
suggested. The next researcher may want to limit the study to women with just recurrent 
W C  as this study showed a decrease in W C  in women supplementing zinc. Or she may 
want to expand to include greater numbers of subjects with recurrent or resistant 
trichomoniasis as prior research has shown zinc to be effective at eradicating this infection. 
Having several study groups, taking different dosages of zinc such as 15 mg, 30 mg, 45 mg, 
75 mg up to 100 mg, would also provide needed information. This study could also 
incorporate serum zinc measurements to supply additional data related to zinc deficiency. It 
is possible that the effects of zinc supplementation are not evident in a six month time 
frame. A study for a one year period of time may provide different results.
It is also possible that starting with a population prone to vaginal infections skewed 
the results. A study encompassing a random sample of all women might decrease the 
incidence in general and provide better insights into the effects of zinc supplementation.
A recent study shows a possible link between cigarette smoking and BV (Brunk, 
1999). Therefore, further research should include data collection on the incidence of 
tobacco use. Using a topical zinc treatment for recurrent vaginitis, such as a suppository or 
cream, may also be worth investigating.
Implications
Application to Practice
It is estimated that one-half of adult women in the US consume less than 7.5 mg of 
dietary zinc daily (Wood & Zheng, 1997). The US RDA for zinc in adult women is 12 mg. 
The study participants consumed an average of 5.86 mg daily, and were known to suffer 
from recurrent vaginal infections. Since a decrease in the incidence of W C  was noted, and 
no long-term detriments to zinc supplementation are documented, women might benefît 
from daily zinc supplement to prevent recurrent W C . The noted zinc deficiency alone in
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the subjects, known to be prone to recurrent vaginal infections, suggests the need to increase 
zinc either by improved nutritional intake or by supplementation.
Summarv
Although this study did not show a statistically significant difference in the 
incidence of overall vaginitis in women taking a zinc supplement versus a placebo, it is still 
intriguing to note that women prone to vaginal infections were found to have inadequate zinc 
intake based on a 24 hour diet recall, taking in on average less than half the RDA of zinc. It 
is also noteworthy that women supplementing zinc did experience a decrease in the 
incidence of recurrent W C . Clinically, if one encounters a woman with recurrent vaginal 
infections, it may be prudent to administer a 24-hour diet recall to investigate the possibility 
of a zinc deficiency.
Vaginitis is a condition of multiple and interrelated causation. One potentially 
contributing factor is inadequate zinc intake. While this factor was not statistically 
supported in this study, this researcher recommends a larger, more complex and 
longitudinal study.
A main function of the nursing profession is to assist the client to recognize 
relationships among the physiological, psychological, sociocultural, developmental, and 
spiritual components of life. In regards to recurrent vaginitis, the advanced practice nurse 
needs to go beyond examination of the woman's vaginal symptoms, and explore with the 
client her lifestyle practices. Hygiene, sexual practices, smoking, and poor dietary habits 
may all be contributing factors to recurrent vaginal infections.
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APPENDICES
Appendix A 
Subject’s Consent Form 
I understand that this is a study of recurrent vaginal infections. It is estimated that one-half of 
women in the United States may not get enough zinc in their diet. Zinc deficiency is associated with the 
body’s immune system not working well. The knowledge gained through this study is expected to help 
nurses and physicians provide helpful information to women in preventing recurrent vaginal infections.
I also understand that:
1.) Participation in this research study is voluntary.
2.) Participation in this research study will involve me taking either a zinc supplement (30 mg of zinc) as 
a capsule, or a placebo capsule (a gelatin capsule filled with com starch) on a daily basis.
3.) Calcium and iron can decrease the amount of zinc absorbed by your body. Therefore, your zinc 
supplement or placebo should be taken two hours before or after any dairy products, calcium supplements, 
antacids, iron supplements, or multi-vitamins containing calcium or iron. Attached is a list o f low calcium 
and low iron foods which you may take the zinc supplement with.
4.) 1 have been selected to participate in this study because 1 have had at least two clinician diagnosed 
vaginal infections in a six month time period, or one infection that has not gotten better.
5.) There are no known physical or emotional risks involved with taking zinc supplements.
6. ) 1 will need to be examined by the researcher three times in the six month study. Once to receive 
instructions and the supplement, once at three months into the study, and again at six months. These visits 
will be free o f charge.
7.) There will be no cost, other than transportation to and from the office, involved in my participation.
8.) The information 1 provide, and the results o f my vaginal exam will be kept strictly confidential. Data 
will be coded so that identification of individual participants will not be possible.
9.) A summary o f the study results will be made available to me upon request. Please initial here if you 
would like to receive a copy of the study results____________________.
10.) If I develop symptoms o f a  vaginal infection, I am free to visit the researcher, or another clinician, to 
seek treatment. These visits for vaginal symptoms will be free o f charge during the six month study. The
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researcher will need to have any such infection recorded for her study, so I will need to provide that 
information to her if care was sought through another health care provider, or if I used over the counter 
remedies.
11.) I will also need to report to the researcher if I take any oral antibiotics during the course of the study.
1 acknowledge that;
1.) I have been given the chance to ask questions regarding this research study, and these questions have 
been answered to my satisfaction.
2.) In giving this consent, I understand that my participation is voluntary and 1 may stop at any time using 
the postcard with my patient identification number provided by Bonnie Bartz without it affecting the care 1 
receive from her. the physicians, or staff at Alpena OB/GYN.
3.) 1 give permission to the researcher to release information obtained in this study to scientific literature.
I understand that 1 will not be identihed by name.
4.) Phone numbers of the researcher and the chairperson at Grand Valley State University (GVSU) Human 
Research Review Committee are listed below. I understand 1 may contact them for questions about the 
research. Researcher Bonnie Bartz (517)356-0504. Chairperson: Dr. Phyllis Gendler (616) 895-3516. 
For questions about your rights in the study please contact Paul Huizenga at (616) 895-6611.
5.) I acknowledge that I have read and understand the above information, and that I agree to participate in 
this study.
Participant's Signature Witness
Date Date
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Name
Address 
Phone # 
D O B _  
Race__
Occupation _____
Medical Problems 
Food Allergies___
Contraceptive Use_
Appendix B 
Researcher’s Notebook
Pt. m.#_
Age
Current medications, herbs, vitamins, OTC products.
AB
Documentation of previous episodes of vaginitis
Date Date
Svmptoms Svmptoms
pH pH
KOH whiff KOH whiff
Wet Mount Wet Mount
Phvsical exam Phvsical exam
Treatment Treatment
Taken as directed? Taken as directed?
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Pt. ID.#
Date Date
Svmptoms Symptoms
pH pH
KOH whiff KOH whiff
Wet Mount Wet Mount
Phvsical exam Phvsical exam
Treatment Treatment
Taken as directed? Taken as directed?
Study Consent Form Signed________
Instructions Reviewed with Participant. 
Capsule A or B
.(Date)
.(Initials)
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Exam Data Pt. ID. #
Initial Exam ______________________(Date)
Symptoms______________________________
pH _______________  KOH Whiff Test
Wet Mount ___________________________
Physical Exam 
Treatment __
Taken as directed?
Intercourse or contraceptive use within 24 hours prior to exam?
Three Month Exam _____________________ (Date)
Symptoms____________________________________
pH _______________  KOH Whiff Test
Wet Mount ___________________________
Physical Exam 
Treatment
Taken as directed?
Intercourse or contraceptive use within 24 hours prior to exam?
Final Six Month Exam
Svmptoms
(Date)
pH KOH Whiff Test
Wet Mount
Phvsical Exam
Treatment
Taken as directed?
Intercourse or contraceptive use within 24 hours prior to exam?
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Pt. ID.#_
Significant Events During Study 
Episodes of vaginal symptoms
Svmptoms
(Date)
dH KOH Whiff Test
Wet Mount
Physical Exam
Treatment
Taken as directed?
Symptoms. 
pH ---------
Wet Mount
Physical Exam 
Treatment
Taken as directed?
.(Date)
KOH Whiff Test
Symptoms. 
pH _____
Wet Mount
Physical Exam 
Treatment
Taken as directed?.
.(Date)
KOH Whiff Test
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Pt. ID.#_
Medications Taken
Date Date
Diagnosis Diagnosis
Prescription Prescription
Length of treatment Length of treatment
Date Date
Diagnosis Diagnosis
Prescription Prescription
Length of treatment Length of treatment
Major Diet Changes
Date ______________
Description
Change in Sex Partner
Date ________________
Date ________________
Major Change in Life Stressors
Date ________________________
Date ________________________
Date _______________________
Incident. 
Incident. 
Incident
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Appendix C 
Patient Instructions
Dear Potential Study Participant,
Thank you for considering being involved in this study. As a sufferer of recurrent 
vaginal infections, you know first hand the pain and frustration that comes with this illness. 
One of the most frustrating things for me, as a nurse, is not being able to tell you how to 
prevent these infections from happening. With this study, I hope to be able to show that 
zinc supplementation can help break this aggravating cycle. In order for the study to be 
successful, it is essential that you follow these simple guidelines below. If you have 
questions or concerns at any time, please feel free to call me or Kendra Robinette at the 
office (356-0504 or 734-2586).
This study involves two groups of participants. One group will receive a placebo (a 
capsule with just a filler inside). The other group will receive an actual zinc supplement. 
There will be three times in the next six months I need to see you. Your first appointment 
will be to receive your capsules, sign the consent form, answer your questions, and get a 
vaginal exam done. The second appointment will be at three months into the study. At that 
appointment, you will need to bring in your capsule bottle. Kendra will be counting your 
remaining capsules to assure that you are taking them on a regular basis. Please don’t 
forget your bottle. You will receive your second vaginal exam at that time. The third and 
final visit will be at the completion of the study, in six months. This appointment will be a 
repeat of the three month appointment. The vaginal exams are being done to determine if 
your vagina is in a healthy state, or if there is any yeast or bacteria present. I hope to see 
that over time, the group taking zinc will show an improvement in the overall health of their 
vaginas.
You will not know if you are taking zinc or the placebo until the end of the study. 
Neither will I. Kendra is keeping track of that information. That is why your bottles are 
only marked A or B. It is important in research to keep that data confidential for several
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reasons. One is if you knew you were taking a placebo, you would be less inclined to take 
it on a daily basis. The other is if the researcher knew who was in the zinc group and who 
was in the placebo group, I might start looking for improvements in the zinc group, and thus 
skew the data I get from your vaginal exams.
Calcium and iron can make your body absorb less zinc. For that reason. I’m asking 
you to take your capsule at least two hours before or after you eat any foods, or take any 
vitamins containing calcium or iron. I suggest that if you take a multivitamin, you take it in 
the morning. Then, take your zinc or placebo capsule at bedtime either with just a glass of 
water, or with a food that does not contain calcium or iron. Many antacids contain calcium, 
so please avoid any antacids for two hours before or after your capsule. Below is a list of 
low calcium and iron foods you may take your capsule with.
Foods that can be taken with your capsule
Graham crackers Toast
Soda crackers Vegetables
Tea (without milk or creamer) Jell-0
Cookies Cake
Fruit pie (without ice cream or raisins) Juice (not calcium enriched)
Prunes Fruit
If at any time during the study you develop symptoms of a vaginal infection, please 
call and make an appointment with me. I will see you free of charge for this appointment. 
If you do have a vaginal infection, you will be given the normal treatment. I will not be able 
to supply the prescription free of charge. If you have an infection that is not responding to 
treatment, I may find it necessary to perform a lab culture. I will not be able to supply the 
lab work free of charge. If you develop a infection on the weekend, or for some other 
reason, cannot make it in to see me, you may use an over-the-counter treatment, or see
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another health care provider, but be sure you report to me any treatments you use during the 
study.
You have been supplied a postage paid postcard. If for any reason, you wish to no 
longer participate in the study, simply drop the postcard in the mail. It has only your patient 
identification number on it. You will not be reprimanded, nor in any way treated differently 
by me or any of the staff at Alpena OB/GYN. No explanation is necessary.
I know this is a big commitment of time and energy on your part. I want to assure 
you that all information is confidential, data will be recorded with your patient identification 
number only, not your name. After the data has been processed, the individual records will 
be destroyed. I want to thank you for your participation. It is my hope that from this small 
study, a much larger study can be done that could eventually bring hope and relief to 
thousands of fellow vaginal infection sufferers.
With thanks and appreciation.
Bonnie R. Bartz
Women’s Health Nurse Practitioner
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Appendix D
Data Collected for Placebo Groupg
Subject 
9222- 
Initial visit
4.3 +2 yeast Scant d/c,
mild
irritation
NA Diflucan
3 mos. 
visit
5.3 - NA NA
6 mos. 
visit
4.5 occ. clue 
cell
- NA NA
Subject 
2550- 
initial visit
4.5 +2 clue 
cells
+ Scant d/c NA Flagyl
3 mos. 
visit
4.0 - • NA NA
6 mos. 
visit
4.5 • - NA NA
Subject 
5783- 
Initial visit
5.5 +3 clue 
cells
+ green d/c 
with odor
NA Flagyl for 
7 days 
then
Flagyl 500 
m gx 1 
with
intercourse
3 mos. 
visit
4.5 - d o  odor NA IC
6 mos. 
visit
NA + d o  odor 
and green 
d/c
NA Phone
interview
Subject 
4269- 
Initial visit
4.2 +1 clue 
cells
NA NA
3 mos. 
visit
4..0 +2 WBCs, 
neg. clue 
cells
NA NA
6 mos. 
visit
4.3 - NA NA
Subject 
5495- 
Initial visit
4.8 NA NA
3 mos. 
visit
4.5 1 yeast, +1 
WBCs
- NA NA
6 mos. 
visit
4.3 +3 clue 
cells
NA IC
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Subject 
10642- 
Initial visit
5.0 few RBCs mucousy
/creamy
d/c
NA NA
3 mos. 
visit
5.0 - - - NA NA
6 mos. 
visit
4.8 Few
WBCs
copious
mucousy
d/c
NA NA
Subject 
3248- 
Initiai visit
4.8 +2 clues scant 
milky d/c
NA Cleocin 
vag. cream
3 mos. 
visit
4.5 + 1 yeast white d/c 
and itching
NA Diflucan 
150 mg X 
3, then 
Diflucan 
100 mg 
every week 
X 8 weeks
6 mos. 
visit
4.2 + 1 yeast - mild
itching
NA NA
Subject 
8441 - 
Initial visit
4.0 +1 yeast Red vulva, 
scant white 
d/c
NA Terazol7 
vag. cream
3 mos. 
visit
4.5 - - NA NA
6 mos. 
visit
4.5 RBCs - spotting NA NA
5/99 Self-tx’d yeast Diflucan
6/99 Self-tx’d yeast After abx. Diflucan
Subject 
3206- 
Initial visit
4.3 +4
lactobacilli
NA NA
3 mos. 
visit
not
recorded
+2 yeast Scant d/c
with
itching
NA Diflucan
6 mos. 
visit
4.3 +1 yeast Slight itch 
with scant 
d/c
NA Diflucan
Subject 
10217 - 
Initial visit
4.5 +1 clue 
cells
+ Red vulva 
with slight 
irritation
NA Flagyl
3 mos. 
visit
5.5 +4 clue 
cells
+ NA Metro-gel
6 mos. 
visit
5.3 +4 clue 
cells
+ Irritation, 
milky d/c, 
odor
Candida
albicans
Flagyl bid 
for 7 days, 
weekly X 
4, and 
Diflucan
7/13/99 5.5 +4 clue + Burning, Heavy Flagyl for
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visit cells tearing, 
odor, ex. 
red, thick 
yellow d/c
Gardner-
ella
subject 
and her 
partner
Subject 
10800- 
Initial visit
4.5 +4 clues + Slight 
greenish 
yellow d/c
NA Cleocin 
vag. cream
3 mos. 
visit
4.5 Yellow d/c
with
burning
NA NA
6 mos. 
visit
Note. The dosages of vaginitis treatments used were standardized as specified on page 57, 
unless otherwise specified. Abbreviations: d/c = discharge, mod. = moderate, NA = Not 
Applicable, WBCs = White Blood Cells, RBCs = Red Blood Cells, IC = Insufficient 
criteria to provide prescription for treatment.
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Appendix E
Data Collected for Zinc Group
Subject
5756
Initial Visit
4.5 +1 clue 
cells
NA IC
3 mos. 
visit
4.0 - - NA NA
6 mos. 
visit
4.3 +2 clue 
cells
- Scant d/c NA IC
3/26/99 Self-tx’d yeast Mycelex 7
5/29/99 Self-tx’d yeast Mycelex 7
Subject
7873
Initial visit
5.2 + 1 clue 
cells
+ Red vulva NA Flagyl
3 mos. 
visit
4.8 + 1 clue 
cells
- Mod. 
milky d/c
NA IC
6 mos. 
visit
4.8 +1 clue 
cells
- Dry vagina NA IC
Subject
5846
Initial visit
4.5 NA NA
3 mos. 
visit
5.0 RBCs Spotting,
slight
burning
NA NA
6 mos. 
visit
4.8 WBCs - Small d/c NA NA
5/14/99
visit
4.8 +4 clue 
cells
+ +4 yellow 
d/c,
burning
NA Flagyl
6/7/99 visit Telephone
call
+ Same
symptoms
NA Cleocin 
vag. cream
Subject
7854
Initial visit
5.0 + 1 clue 
cells
+ Slight d/c 
with odor
NA Flagyl X 7 
days, then 
1 Hagyl 
po with 
intercourse
3 mos. 
visit
5.0 +2 clue 
cells
+ Slight d/c 
with odor
NA Metro-gel
6 mos. 
visit
4.8 +1 clue 
cells
+ Slight d/c 
with odor
NA Flagyl
Subject
8990
Initial visit
5.5 +1 clue 
cells
+ Burning,
odor
NA Flagyl
3 mos. 
visit
4.8 +1 clue 
cells
Burning,
itching
NA Metro-gel
6 mos. 4.5 +1 clue - - Shows Cleocin
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visit cells heavy
gardnerella
vag. cream 
(on Flagyl 
for d/c in 
stool).
Subject
2316
Initial visit
5.0 +4 yeast, 
+2 clue 
ceils
+ Yellow d/c, 
red vulva
NA (Note: 
pt. cannot 
tolerate 
Flagyl)
Cleocin 
vag. cream 
and a 
series of 3 
Diflucan
3 mos. 
visit
4.9 +2 clue 
cells
+ Burning NA Metro-gel
6 mos. 
visit
4.5 +4 clue 
cells
+ Burning,
d/c,
irritation, 
red vulva
Candida
albicans
Metro-gel
and
Diflucan
4/20/99
visit
5.0 +4 clue 
cells, +1 
yeast
+ Burning, 
d/c with 
odor
Candida
albicans
Cleocin 
vag. cream 
and
Diflucan
5/26/99
visit
5.0 +3 clue 
cells
+ Burning, 
itching, d/c
NA Cleocin
and
Diflucan
Subject
5022
Initial visit
5.0 +4 clue 
cells
+ + Burning, 
d/c with 
odor
NA Metro-gel
3 mos. 
visit
4.5 +2 clue 
cells
Copious 
d/c with 
minor 
irritation
NA Metro-gel
6 mos. 
visit
NA Not done - 
on menses
No
complaints
NA NA
Subject
5916
Initial visit
5.3 +1 clue 
cells
+ Milky d/c
with
burning
NA Flagyl
3 mos. 
visit
4.5 NA Prophylact 
ic Hagyl 
and
Diflucan at 
end of 
menses
6 mos. 
visit
4.8 +1 clues + Slight itch 
and odor
NA Metro-gel
4/12/99
visit
5.2 +1 clues + SUght 
odor and 
irritation
NA Hagyl
4/26/99 5.3 + l clue + Red vulva. Shows e. Cleocin
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visit cells, +1 
yeast
scant d/c, 
odor and 
irritation
coli vag. cream 
and
Diflucan,
then
Keflex
5/25/99
visit
5.0 +2 yeast, 
+1 clue 
cells
+ Chunky 
milky d/c 
with odor, 
red vulva
NA Flagyl and 
Diflucan
7/26/99
visit
4.3 +4 yeast Itching 
and d/c
NA Diflucan x 
3, then 
weekly 
Diflucan x 
12 weeks
8/3/99 visit 5.0 +1 clue 
ceils
+ Burning NA Flagyl
8/12/99
visit
4.5 Itchy d/c NA IC
8/30/99 5.0 +1 clue 
cells
+ Burning NA Cleocin 
vag. cream
Subject
1419
Initial visit
5.0 +4 clue 
cells
+ NA Pt.
declined
treatment
3 mos. 
visit
5.3 +4 clue 
cells
Mod. 
yellow d/c
NA Cleocin 
vag. cream
6 mos. 
visit
5.3 +1 clue 
cells, +1 
yeast
+ Scant 
creamy d/c
NA Flagyl
Subject 42 
Initial visit
5.0 + 1 clue 
cells,+1 
yeast
Slight d/c 
with itch
NA Diflucan 
and Flagyl
3 mos. 
visit
4.8 Mucousy 
yellow d/c
NA NA
6 mos. 
visit
4.8 RBCs Spotting NA NA
3/25/99
visit
Telephone
call
NA NA Itching NA Diflucan
Subject 
11131 
Initial visit
4.5 +4 clue 
cells
+4 d/c NA Flagyl
3 mos. 
visit
4.0 - White d/c NA NA
6 mos. 
visit
4.3 - Spotting NA NA
Subject
5195
Initial visit
4.8 +3 clue 
cells
Normal NA IC
3 mos. 
visit
5.3 +3 clue 
cells
Thick 
white d/c, 
itching
NA Flagyl
6 mos. 4.0 WBCs - Creamy NA NA
57
visit d/c
7/25/99
visit
Telephone
call
NA NA Itching, 
white d/c
NA Diflucan
Subject
3238
Initial visit
5.5 + Milky d/c 
at introitus
NA Flagyl
3 mos. 
visit
4.5 Mod.
lactobacilli
- - NA NA
6 mos. 
visit
Not
completed
Subject
3256
Initial visit
5.0 +2 clue 
cells
NA IC
3 mos. 
visit
5.0 + 1 clue 
cells
- Spotting NA NA
6 mos. 
visit
4.8 WBCs Mod. 
yellow/ 
green d/c
NA NA
Subject 
10054 
Initial visit
4.6 + 1 clue 
cells
Thick 
white d/c
NA NA
3 mos. 
visit
4.5 Normal NA NA
6 mos. 
visit
Telephone
call
NA NA Normal NA NA
unless otherwise specified. Abbreviations: d/c = discharge, mod. = moderate, NA = Not 
Applicable, WBCs = White Blood Cells, RBCs = Red Blood Cells, IC = Insufficient 
criteria to provide prescription for treatment.
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Appendix F 
Vaginitis Treatment Protocol
The protocol within the practice where the researcher is employed states the 
appropriate medication for treating a yeast infection is considered to be one of the 
following: fluconazole (Diflucan) 150 mg single oral dose; terconazole (Terazol) 80 mg 
vaginal suppository, one suppository nightly for three nights; terconazole vaginal cream 
(Terazol 7), one applicator vaginally nightly for seven nights; miconazole (Monistat) 2% 
cream, 5 grams vaginally for 7 nights, tioconazole (Vagistat) 6.5% cream, 5 gram single 
dose. Any of these treatments are deemed adequate according to research done by Sobel, 
Faro, Force, Foxman, Ledger, Nyiijesy, Reed and Summers ( 1998), and Roe and Gudi, 
(1997).
Appropriate treatment for a bacterial vaginal infection includes; metronidazole 
(Flagyl) 500 mg orally twice a day for 7 days. Alternative treatments include clindamycin 
2% vaginal cream (Cleocin), 1 applicator vaginally nightly for 7 nights; clindamycin 300 mg 
orally twice a day for 7 days (used only with resistant infections); metronidazole vaginal 
cream (Metro-gel), one applicator vaginally every night for 5 nights (Roe & Gudi, 1997).
If a woman returned after treatment of vaginitis with complaints of a vaginal 
infection within 6 months of the initial complaint, she again underwent physical exam, wet 
mount, KOH whiff test, urogenital culture, and pH. It was also determined that she had 
taken all medications as prescribed initially. This differentiates between recurrent infection 
as opposed to inadequate treatment. The urogenital culture helps determine if there are 
organisms present other than yeast or gardnerella such as E. coli.
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Appendix G
Summary of Infections Prior to and During Study - Placebo Group (N=l I)
H
9222 5BV Yeast - - - 0
2550 2 Yeast BV - - - 0
5783 2BV BV - BV - 1 BV
4269 2BV - - - - 0
5495 3BV - - - - 0
10642 4 Mixed - - - - 0
3248 1BV,2
Yeast
BV Yeast 1 Yeast
8441 3 Yeast Yeast - - 2 Yeast 2 Yeast
3206 2BV - Yeast Yeast - 2 Yeast
10217 2BV, 1 
Yeast
BV BV Mixed BV 2BV, 1 
Mixed
10800 IBV, 1 
Mixed
BV - 0
Totals for
Placebo
Group
38 Total: 
23 BV,
10 Yeast, 
5 Mixed
Included in 
Prior 
Infections 
(pre-
treatment)
9 Total: 
3BV,
5 yeast, 
1 mixed
Summary of Infections Prior to and During Study - Zinc Group (N=15)
5756 2 Yeast - - - 2 yeast 2 Yeast
7873 IBV, 1 
Yeast
BV - 0
5846 3BV - - - 2BV 2BV
7854 IBV, 1 
Mixed
BV BV BV - 2BV
8990 2BV BV BV BV - 2BV
2316 4BV,4
Yeast
Mixed BV Mixed 2 Mixed 3 Mixed, 1 
BV
5022 4BV BV BV - IBV
5916 3 Yeast BV BV 3BV.2 
Mixed, 1 
Yeast
4BV.2 
Mixed, 1 
Yeast
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1419 2BV BV BV Mixed IBV, 1 
Mixed
42 6 Yeast Mixed - - 1 Yeast 1 Yeast
11131 2BV BV - - - 0
5195 3 Yeast BV - 1 Yeast 1 Yeast, 1 
BV
3238 2BV - - - - 0
3256 IBV, 1 
Mixed, 1 K. 
pneumonia
0
10054 2BV,2
Mixed
- - - 0
Totals for 
Zinc Group
57 total: 
31 BV,
19 Yeast, 
6 mixed, 
1 other
Included in 
Prior 
Infections 
(pre-
treatment)
26 Total: 
14 BV,
6 Yeast,
6 Mixed
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